Prospective Multicenter Study on Subcutaneous Concentrated Desmopressin for Home Treatment of Patients with von Willebrand Disease and Mild or Moderate Hemophilia A

Summary

Desmopressin is the treatment of choice in most patients with von Willebrand disease (vWD) and mild hemophilia A (HA). Several studies have demonstrated that the intravenous and subcutaneous route of administration are equivalent in terms of pharmacokinetics and clinical efficacy. Home therapy of vWD and mild HA is desirable but so far there have been only a few case reports and no prospective studies. We report the results of a prospective study of home therapy in patients with vWD and mild-moderate HA using concentrated desmopressin self-administered subcutaneously. Clinical efficacy and safety were assessed by the patient using a questionnaire and direct interview. The patients were instructed on self-administration and dosage, reasons for treatment, recognition of side effects and recording clinical efficacy. The study lasted 12 months (range 6-17). During this time, 43/100 (43%) of the enrolled vWD patients (median basal VIII: C 24%, range 9-49) and 36/69 (52%) of HA patients (median basal VIII: C 10%, range 5-34) self-administered the drug. A total of 127 bleeding episodes requiring treatment occurred in patients with vWD and 92 in HA patients. There were 10 treatment failures of which 7 required in-hospital treatment. Overall, in 94% of treatments (excluding menorrhagia) the response was scored as excellent or good. In 86% of treated episodes of menorrhagia the response was scored as excellent or good. According to the patients, 81% of clinical situations would have required in-hospital treatment. Mild flushing, with or without headache, was the only consistent side-effect, reported in about 30% of treatments. In conclusion, home therapy with subcutaneous desmopressin for von Willebrand disease and hemophilia A was well accepted by the patients and proved feasible, efficacious and safe for the prevention or prompt treatment of bleeding.

• References

• 1 Rodeghiero F, Castaman G, Mannucci PM. Clinical indications for desmopressin (DD A VP) in congenital and acquired von Willebrand disease. Blood Reviews 1991; 5: 155-161
• 2 Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand’s disease. Blood 1987; 69: 454-459
• 3 Castaman G, Rodeghiero F. Current management of von Willebrand’s disease. Drugs 1995; 50: 602-614
• 4 Mannucci PM. Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders. Blood 1988; 72: 1449-1455
• 5 Lethagen S, Harris AS, Nilsson IM. Intranasal desmopressin (DDAVP) by spray in mild haemophilia A and von Willebrand’s disease type I. Blut 1990; 60: 187-191
• 6 Rose EH, Aledort LM. Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease. Ann Intern Med 1991; 114: 563-568
• 7 Lethagen S, Ragnarson Tennvall G. Self-treatment with desmopressin intranasal spray in patients with bleeding disorders: effect on bleeding symptoms and socioeconomic factors. Ann Hematol 1993; 66: 257-260
• 8 Ghirardini A, Mariani G, Iacopino G, Tirindelli MC, Solinas S, Moretti T. Concentrated DDAVP: further improvement in the management of mild factor VIII deficiencies. Thromb Haemost 1987; 58: 896-898
• 9 Ghirardini A, Chistolini A, Tirindelli MC, Di Paolantonio T, Iacopino G, Mariani P, Chirletti P, Agrestini F, Mariani G. Clinical evaluation of subcutaneously administered DDAVP. Thromb Res 1988; 49: 363-372
• 10 Mannucci PM, Vicente V, Alberca I, Sacchi E, Longo G, Harris AS, Lindquist A. Intravenous and subcutaneous administration of desmopressin (DDAVP) to hemophiliacs: pharmacokinetics and factor VIII responses. Thromb Haemost 1987; 58: 1037-1039
• 11 Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. DDAVP: a new pharmacological approach to the management of haemophilia and von Willebrand’s disease. Lancet 1977; 1: 869-872
• 12 Mariani G, Mannucci PM, Cattaneo M. (eds) Desmopressin in bleeding disorders. Plenum Press; New York: 1993
• 13 Kohler M, Hellstern P, Miyashita C, von Blohn G, Wenzel E. Comparative study of intranasal, subcutaneous and intravenous administration of desamino-D-arginine vasopressin (DDAVP). Thromb Haemost 1986; 55: 108-111
• 14 Lethagen S, Harris AS, Sjorin E, Nilsson IM. Intranasal and intravenous administration of desmopressin: effect on FVIII/vWF, pharmacokinetics and reproducibility. Thromb Haemost 1987; 58: 1033-1036
• 15 Smith TJ, Gill JC, Ambroso DR, Hathaway WE. Hyponatremia and seizures in young children given DDAVP. Am J Hematol 1989; 31: 199-202
• 16 Weinstein RE, Bona RD, Altman AJ, Quinn JJ, Weisman SJ, Bartolomeo A, Rickies FR. Severe hyponatremia after repeated intravenous administration of desmopressin. Am J Hematol 1989; 32: 258-261
• 17 Mannucci PM, Lusher JM. Desmopressin and thrombosis. Lancet 1989; 2: 675-676
• 18 Bond L, Bevan DU. Myocardial infarction in a patient with hemophilia treated with DDAVP. N Engl J Med 1988; 318: 121
• 19 Hartmann S, Reinhart W. Fatal complication of desmopressin. Lancet 1995; 1: 1302-1303
• 20 Mariani G, Ghirardini A, Schinaia N. Epidemiology of mild and moderate hemophilia A and von Willebrand’s disease. In Mariani G, Mannucci PM, Cattaneo M. (eds) Desmopressin in bleeding disorders. Plenum Press; New York: 1993: 233-238